Systemic and topical treatments for autoimmune bullous disease: A network meta-analysis of randomized controlled trials.

References:

• Sadik CD, Schmidt E, Zillikens D, Hashimoto T. Recent progresses and perspectives in autoimmune bullous diseases. J Allergy ClinImmunol 2020;145:1145–1147. doi: 10.1016/j.jaci.2020.02.020.
• Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Intraepithelial autoimmune blistering dermatoses: Clinical features and diagnosis. J Am Acad Dermatol 2021;84:1507–1519. doi: 10.1016/j.jaad.2020.11.075.
• Montagnon CM, Lehman JS, Murrell DF, Camilleri MJ, Tolkachjov SN. Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy. J Am Acad Dermatol 2021;85:18–27. doi: 10.1016/j.jaad.2020.05.161.
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.
• Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med 2015;162:777–784. doi: 10.7326/m14-2385.